Ou Kang Pharmaceutical announced that the company recently received an Establishment Inspection Report (EIR) issued by the FDA. According to the inspection report, no FDA-483 inspection defects were announced officially, which means that the company passed the on-site inspection by the US FDA.
欧康医药：通过美国FDA现场检查
Ou Kang Pharmaceuticals: Passed the on-site inspection of the US FDA.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.